Metrics to compare | NTI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNTIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −7.0x | −0.3x | |
PEG Ratio | −0.08 | −0.21 | 0.00 | |
Price/Book | 37.0x | 5.4x | 2.6x | |
Price / LTM Sales | 4.8x | 2.6x | 3.0x | |
Upside (Analyst Target) | - | 109.0% | 58.5% | |
Fair Value Upside | Unlock | 9.0% | 7.1% | Unlock |
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.